title: The presence of anti-p53 antibodies in sera from patients with oesophageal carcinoma: correlation to treatment, tumour volume and survival.
abstract: BACKGROUND
  A correlation between mutations in the p53 gene and the presence of anti-p53 antibodies in sera has been reported. The aim of the present study was to analyse anti-p53 antibodies in sera from patients with oesophageal carcinoma and their implications for clinical outcome and survival
  
  
  METHODS
  Between 1996 and 2002, patients treated for oesophageal carcinoma at the Department of Oncology, Uppsala University Hospital, Sweden, were asked to donate serum samples during treatment and follow-up. A total of 42 patients, with serum samples collected prior to therapy, were analysed for expressions of anti-p53 antibodies using a commercially available sandwich ELISA (Dianova, Hamburg, Germany).
  
  
  RESULTS
  Anti-p53 antibodies did not correlate with investigated laboratory parameters. No correlation between anti-p53 antibodies and tumour volume was found (n=31; r=0.08;p=0.66). Anti-p53 antibodies as a continuous variable was not associated with survival (p = 0.42). Neither was the presence of anti-p53 antibodies (according to defined cut-off of 1.1, provided by the manufacturer) associated with survival (p = 0.99).
  
  
  CONCLUSIONS
  The presence of anti-p53 antibodies correlated neither to tumour volume nor to clinical parameters.
authors.affiliation: Department of Oncology, University Hospital, Uppsala, Sweden.
authors.forename: Stefan
authors.initials: S
authors.lastname: Bergström
authors.forename: Martin
authors.initials: M
authors.lastname: Dreilich
authors.forename: Gunnar
authors.initials: G
authors.lastname: Wagenius
authors.forename: Daniel
authors.initials: D
authors.lastname: Brattström
authors.forename: Anders
authors.initials: A
authors.lastname: Larsson
authors.forename: Patrik
authors.initials: P
authors.lastname: Hesselius
authors.forename: Michael
authors.initials: M
authors.lastname: Bergqvist
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000912:Antibodies, Neoplasm / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D004797:Enzyme-Linked Immunosorbent Assay; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D010166:Palliative Care; D011300:Preoperative Care; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D016159:Tumor Suppressor Protein p53